Pharma Focus Asia

Tergus Pharma to Build a New Commercial Manufacturing Facility with Great Point Partners


Tergus Pharma partners with Great Point Partners to build a new commercial manufacturing facility.


A 100,000 square feet new expansion will provide comprehensive services from development through manufacturing and will become a Contract Development and Manufacturing Organisation, or CDMO.

The new US$ 35million facility will be provide an employment for 200 people over the next five years after building a new headquarters and a commercial manufacturing centre.

Tergus announced a partnership with the Great Point Partners (GPP), a healthcare invest firm.

New construction provides Topical Formulation development, In Vitro Release Testing (IVRT),  in vitro Permeating Testing (IVPT), Analytical services, Skin Biology, and Clinical Trial Materials (CTM) manufacturing services for branded and generic dermatology products.

GPP's investment will allow Tergus Pharma to build a state-of-art commercial manufacturing building in the Raleigh-Durham. This new Construction will increase the current capacity by over 400 per cent.

The new facility is expected to be operational in early 2020.


NameTergus Pharma
BudgetUS$ 35 million
Parties InvolvedGreat Point Partners (GPP)
ScheduleScheduled to be open in early 2020
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference